News
ETNB
11.64
+2.92%
0.33
Buy Rating Affirmed for 89bio’s Pegozafermin: A Promising NASH Treatment with Strong Regulatory Endorsements
TipRanks · 3h ago
Peek Under The Hood: XBI Has 59% Upside
NASDAQ · 21h ago
Analysts Are Bullish on These Healthcare Stocks: 89bio (ETNB), Perspective Therapeutics (CATX)
TipRanks · 1d ago
Insider Trading: RA Capital Buys Stock Worth $15M in LENZ Therapeutics
TipRanks · 2d ago
Weekly Report: what happened at ETNB last week (0318-0322)?
Weekly Report · 4d ago
Noteworthy ETF Inflows: LABU, FDMT, ETNB, ACAD
NASDAQ · 6d ago
Inventiva Phase 2 study for MASH drug meets primary endpoint
Inventiva Phase 2 study for MASH drug meets primary endpoint. Inventiva's drug candidate lanifibranor met its primary efficacy endpoint in the treatment of patients with MASH/NASH and type 2 diabetes. Last week, Madrigal drug Rezdiffra became the first FDA-approved treatment for the liver disorder.
Seeking Alpha · 03/18 21:45
5 Stocks that Analysts Love in March 2024
TipRanks · 03/18 12:35
Ozempic Can't Do It All: A Potential New Blockbuster Is a Reminder of That -- Heard on the Street
Madrigal Pharmaceuticals, maker of a treatment for a fatty liver disease known as NASH, got FDA approval. The company's stock rose 11% on Friday to close above $270. Madrigal shares soared more than 200% in December. The drug, Rezdiffra, is expected to be a multibillion-dollar opportunity.
The Wall Street Journal · 03/18 11:00
Weekly Report: what happened at ETNB last week (0311-0315)?
Weekly Report · 03/18 10:07
NASH drug market expected to surpass $48B by 2035
Healthcare NASH drug market expected to surpass $48B by 2035. Global therapeutic market catering to the widely prevalent liver disease non-alcoholic steatohepatitis is projected to reach $48.3B. North America is set to generate the lion's share of revenue. Europe is anticipated to record the highest CAGR in the NASH treatment market. Madrigal Pharmaceuticals received FDA approval for first U.S.-approved NASH therapy.
Seeking Alpha · 03/16 16:57
AVLX, SGH and ETNB are among pre market losers
On the Move AVLX, SGH and ETNB are among pre market losers. 89bio and iHeartMedia are among the pre market gainers. CERo Therapeutics Holdings and Castle Biosciences are among those that lost in the biotech sector.
Seeking Alpha · 03/15 20:48
Wegovy and Zepbound Cast Shadow Over Madrigal's Liver Drug
FDA approved a liver drug for the condition known as MASH. The drug Rezdiffra was approved late Thursday for MASH, an advanced liver disorder. The FDA's approval of the drug marks a turning point in the battle to get MASH drugs on the market. Biopharma is opening other large markets aside from obesity and diabetes.
Barron‘s · 03/15 20:35
Madrigal climbs amid hopes for new NASH drug; B. Riley upgrades
FDA approves Madrigal Pharmaceuticals' new drug for nonalcoholic steatohepatitis. Rezdiffra is the first U.S.-approved therapy for NASH. B. Riley upgrades the company's stock to Neutral from Sell. The company's shares are up 26% in the premarket.
Seeking Alpha · 03/15 12:19
Analysts Are Bullish on These Healthcare Stocks: 89bio (ETNB), Intuitive Surgical (ISRG)
TipRanks · 03/15 09:20
Madrigal Pharmaceuticals gets first FDA approval for drug targeting liver disease MASH
MarketWatch · 03/14 20:44
FACTBOX-Madrigal's drug wins first US approval for fatty liver disease NASH as rivals circle
Madrigal Pharmaceuticals' drug wins first US approval for fatty liver disease NASH. Madrigal's drug is the first to win regulatory approval to treat a serious type of liver disease. Other companies are also developing treatments for the disease. The race to tap a multi-billion dollar market is intensifying.
Reuters · 03/14 20:09
Madrigal granted FDA approval for NASH therapy
Madrigal Pharmaceuticals' lead asset resmetirom is the first U.S.-approved therapy for a liver condition called nonalcoholic steatohepatitis. The drug will be indicated with diet and exercise for NASH with moderate to advanced liver fibrosis. Madrigal granted FDA approval for NASh therapy for March 14, 2024.
Seeking Alpha · 03/14 19:45
Madrigal and liver drug developers fall ahead of FDA decision on NASH therapy
Madrigal and liver drug developers fall ahead of FDA decision on NASH therapy. Companies focused on developing drugs for a liver disease called nonalcoholic steatohepatitis are among the notable decliners. Madrigal Pharmaceuticals' lead asset, resmetirom, is targeted at NASH.
Seeking Alpha · 03/14 14:42
Liver drug developers outperform as U.S. awaits first NASH drug
Liver drug developers outperform as U.S. Awaits first NASH drug approval. Madrigal Pharmaceuticals awaits FDA clearance for its lead asset resmetirom. The company's shares have soared 16% this year, outperforming the biopharma industry.
Seeking Alpha · 03/13 17:29
More
Webull provides a variety of real-time ETNB stock news. You can receive the latest news about 89Bio, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ETNB
89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone. It conducted a Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics (PK) of pegozafermin.